NCT00723255

Bevacizumab and Temsirolimus in Treating Patients With Recurrent or Persistent Endometrial Cancer

A Phase II Evaluation of Combination Bevacizumab (NCI-Supplied Agent: NSC #70486) and Temsirolimus (CCI-779, NCI-Supplied Agent, NSC #683864) in the Treatment of Recurrent or Persistent Endometrial Carcinoma

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 53 (actual)
• Sponsor: National Cancer Institute (NCI) · NIH
• Sex: Female
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This phase II trial is studying the side effects of giving bevacizumab together with temsirolimus and to see how well it works in treating patients with recurrent or persistent endometrial cancer. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for their growth. Giving bevacizumab together with temsirolimus may kill more tumor cells.

Detailed description

PRIMARY OBJECTIVES: I. To assess the activity of bevacizumab and temsirolimus, in terms of 6-month progression-free survival (PFS) and objective tumor response, in patients with recurrent or persistent endometrial cancer. II. To determine the nature and degree of toxicity of this regimen in these patients. SECONDARY OBJECTIVES: I. To determine the duration of PFS and overall survival of patients treated with this regimen. II. To determine the effects of prognostic factors (i.e., performance status, histological subtype, and grade) in patients treated with this regimen. TERTIARY OBJECTIVES: I. To compare the proportion of patients with objective tumor response and PFS at 6 months receiving the combination of bevacizumab and temsirolimus with those for the single agents bevacizumab and temsirolimus using historical controls. OUTLINE: This is a multicenter study. Patients receive bevacizumab IV on days 1 and 15 and temsirolimus IV on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. After completion of study therapy, patients are followed every 3 months for 2 years, then every 6 months for 3 years, for a total of 5 years.

Conditions

• Recurrent Endometrial Carcinoma

Interventions

Type	Name	Description
BIOLOGICAL	bevacizumab	Given IV
DRUG	temsirolimus	Given IV

Timeline

• Start date: 2008-09-01
• Primary completion: 2011-07-15
• Completion: 2016-01-25
• First posted: 2008-07-28
• Last updated: 2019-07-23
• Results posted: 2015-08-05

Locations

41 sites across 1 country: United States